By targeting the anti-apoptotic modulators (BCL-XL and MCL-1) of melanoma, this combination could provide a new therapeutic efficacy against metastatic melanoma resistant to ongoing treatment [58]. The gene discussed is BCL2L1; the disease is melanoma.